INTRODUCTION
Neuroblastoma is a tumor of much interest to those involved in the immunology of neoplastic diseases. This interest stems from both the clinical evidence that suggests a role for host immune response against this tumor and laboratory evidence for a host immune reaction against tumor associated antigens (1). Neuroblastoma has the highest incidence of spontaneous regression Received for publication 3 April 1978 and in revised form 24Jtuly 1978. of any human neoplasm, primarily in children <1 yr of age (1) (2) (3) . Sometimes neuroblastoma differentiates spontaneously, or after therapy, into a benign form, i.e., ganglioneuroma (4, 5) .
Neuroblastoma was one of the first human tumors to be studied immunologically in vitro (6) (7) (8) . Humoral antibodies to tumor antigens capable of killing neoplastic cells in vitro in the presence of complement were described by Hellstrom et al. (6, 9, 10) and Tamerius et al. (11) . Using a colony inhibition technique, Hellstrom and his associates (6, 9, 10) showed that lymphocytes from patients with neuroblastoma were found to inhibit colony formation in vitro by the patient's own tumor cells and by tumor cells from other patients with the same disease. On the other hand, serum from patients with progressively growing neuroblastoma protected neuroblastoma cells from cytotoxic immune lymphocytes and did not inhibit colony formation.
This serum effect was first believed to be mediated by "blocking antibodies" (9) . Further observations suggested that blocking factors are actually under a variety of circumstances antigen-antibody complexes (12) (13) (14) (15) (16) .
In animal studies, Oldstone (17) showed that in neuroblastoma-bearing mice a deposition of soluble immune complexes can be demonstrated in the kidneys.
In this study ve have investigated and correlated levels of circulating immune complexes (ICS)l with complement (C) components in sera of children with different stages of neuroblastoma.
METHODS Patient population. The diagnosis was based on the following criteria: (a) clinical presentation (abdominal mass, severe diarrhea, cachexia, orbital hematoma) (18) ; (b) characteristic histopathology ofbiopsy (19) ; (c) 24 h urinary excretion of catecholamines over normal age-matched levels (20) .
The patients were classified according to a scheme of staging, based on the extent of dissemination at the time of diagnosis (21) ranging from stage 1, when the tumor is confined to the tissue or organ of origin to stage IV, when distant metastasis in bones, soft tissue, liver, and skin are present. Stage IVs includes patients of stage I and II but with distant metastasis to skin, liver, or soft tissue and not to the bones. For the staging, all patients had a bone marrow biopsy and liver and bone scan. Nine patients had thoracic neuroblastoma, three with involvement of the spinal canal. In 26 patients we found lytic bone lesions. In this retrospective study, we used 123 serum samples of 55 patients of the Memorial SloanKettering Cancer Center, and 12 patients of the Children's Hospital of the University of Heidelberg, Germany. As controls for all determinations, we used sera obtained from healthy age-matched children. They were free of infections and had no malignancies.
Distribution of neuroblastoma patients studied. The distribution of clinical stages of the 67 patients is presented in Table I . C levels and ICS were determined in 123 sera of the 67 patients. These sera were subdivided as follows: sera of patients with no evidence of disease (NED) (n = 66), with active disease (n = 57), before therapy (surgery and [or] chemotherapy) (n = 12), during treatment (n = 85), and after cessation of therapy (n = 26). There were no differences in age between the samples from patients with active disease and those without evidence of disease.
Patient sera. Blood samples (5-10 ml without anticoagulants) were drawn under sterile conditions, allowed to clot at room temperature for 1 h, clarified by centrifugation, fractionated, and stored at -70°C. The serum samples, in this retrospective study, were taken before therapy at time intervals of at least 3 wk in serial follow-up of patients and at irregular time intervals after cessation of therapy.
Measuremlenit of total hemolytic C (TCH550) antd C components. Buffers for C assays were prepared as described (22) . Assays of TCH50 and C components were carried out as before (22) with functionally pure C components C1-C9 and intermediate cells EAC19P, EAC4hU, EACLKP4hu and EAC19P-7hu cells. Functional factor B was assayed with glutathione-treated cells and purified cobra venom factor according to the described methods (23) . Cobra venom factor Naja naja was purified according to the methods described earlier (24) . In the second step ofpurification, Sephadex G-100 (Pharmacia Fine Chemicals, Div. of Pharmacia Inc. N. J.) was used. The purified preparation gave a single band on disk electrophoresis and was free of phospholipase activity. Clq and C3 were determined immunochemically by the Mancini et al. (25) technique using monospecific antisera against these components (26) . Immunoelectrophoretic analysis was carried out by the described methods (27) . Raji cell radioimmunoassay. Raji cell radioimmunoassay for the determination of ICS was carried out according to the method of Theofilopoulos et al. (28) (29) . AHG was prepared by heating purified IgG in a waterbath at 63°C for 30 min, and the protein content of the soluble AHG was again determined.
Radioiodination of rabbit anti-human IgG. Radioiodination of rabbit anti-human IgG with 1251 (New England Nuclear, Boston, Mass.) was performed using the chloramine T method according to McConahey and Dixon (30) . The labeled anti-human IgG was extensively dialyzed against phosphatebuffered saline, pH 7.2, for 36 h. The specific activity ofthe '251_ rabbit anti-human IgG (0.3 mg/ml) was 0.05-0.2 gCi ,ug/ protein.
Biostatistical methods. The Kruskal-Wallis test was used to test for the differences of ICS levels among the various stages of disease and among the treatment groups. The Welch two-sided t test was used to test the differences between the mean values of the complement levels in the patients' sera with the normal control of each (31) .
RESULTS
Levels of TCH5O and C components. Table II presents the mean, standard deviation, and sample size of each of the serum complement component determinations of the patients in the active disease group, the NED group, and the normal control of sera obtained from 15 healthy age-matched children. All values of the hemolytic titers Cl-C9 and factor B are expressed as the percentage of pooled normal serum obtained from the healthy children. Each value represents the first serum sample of each patient. The only significant difference between the mean values of the active disease and NED groups was in the hemolytic Cl titer (P 4 Active disease, lower than control, P < 0.025. § NED, lower than control, P < 0.005. Active disease and NED combined lower than control, P < 0.001. ¶ Active disease and NED combined lower than control, P < 0.002. < 0.002); however, they were on opposite sides of the normal mean. Pooling the active disease and NED groups, the means of the patients' values were not significantly different from the normal controls except for C3 and C8 which were both lower. Because of the large number of comparisons made, the large variability obtained in each test, and the fact that only a small number of determinations were available for some tests, this analysis is meant to indicate the direction of change in C component levels between the two groups. There were no significant correlations between any pair of C components or between any C component and ICS levels. Low C3 hemolytic values were associated with high C3 levels determined immunochemically (Table II) (28) we determined the levels of ICS of 61 patients with different stages of neuroblastoma before, during, and after therapy. Table III presents the mean, median, and range of the ICS levels for each group of neuroblastoma patients subdivided by the stage of the disease and the course of treatment. All normal control values were under 16 ,g/ml. We used only the values of the first determination of each patient so that each patient is represented only once in the analysis. Stage IVs cases were not included in subsequent analyses. 12 patients were studied before therapy, 32 patients during therapy with or without evidence of tumor, and 15 patients after successful treatment and cessation of therapy. As shown in Table III , an association between the stage of the disease and ICS levels was obtained.
The ICS levels are higher in the more advanced stages of disease and in these stages they are higher before treatment than during or after treatment. The increase of ICS levels with respect to disease stages is more evident within the before treatment group; the medians for stages I-IV are: 16, 28, 160, and 1, 100 ,tg/ml, respectively. The decrease of ICS levels over the course of treatment is most evident in stage IV patients; the medians for before, during, and after treatment are 1,100, 51 (combining the results of the two during therapy groups) and 16 .ug/ml, respectively.
Within the NED group no significant differences Immune Complexes in Neuroblastoma between ICS levels could be detected in the during treatment and after treatment groups, and the differences among the stages of the disease were not significant.
The differences between the stages of disease can be seen in Figs. 1 and 2 . In Fig. 1 the cumulative frequencies are shown on log-normal probability paper. For any given ICS level on the abscissa, the corresponding value on the ordinate as determined by the curve gives the proportion of ICS determinations that is less than or equal to that level. As shown, the distributions shift to higher levels with advanced stages, particularly with stage IV. Fig. 2 shows the individual Amount of Immune Complex (pg equivolent AHG/mI) FIGURE 1 Cumulative distribution (percentage) of patients with different stages of neuroblastoma in relation to the amount of ICS. The data are plotted on log normal probability paper. The 50% point is the median of each group. The distribution shifts to higher levels with advanced stages of the disease.
determinations for stages I-IV. It can be seen that the range of the levels increases sharply with the stage of disease. A nonparametric Kruskal-Wallis test for differences in the frequency distributions showed significant differences among the stages of the disease (P < 0.01). However, this is a result of the higher values of ICS in stage IV, which are significantly higher than all of the stages I-III combined (P < 0.005). Although there is evidence of a steady rise with each stage of the disease the differences between stages I-III are not significantly different, possibly because of the small sample sizes.
Compparison of ICS levels with the course of treatmlent. If the ICS levels of the neuroblastoma patients are subdivided by the course oftreatment, there is a significant difference among the three groups (P < 0.05). In 12 patients before treatment was initiated the median of ICS levels was 64, in 32 patients during treatment with or without evidence of disease the median was 27, and in 15 patients after cessation of treatment, the median decreased to 16 ,ug/ml (Table III) .
Within the stage IV group, the differences among before, during, and after treatment groups are significant (P < 0.05) (Fig. 3) . A two-way analysis of variance (31) was also carried out on the log-transformed ICS values, with the stages of the disease and the disease status as the two factors. The conclusions are similar to the results above. Serial data of ICS in neuroblastoma. 18 patients with repeated observations over periods of 1-24 mo were studied. These are 10 patients with NED and 8 with active disease. However, most of the NED 50 ,ug/ml. In Fig. 4 , patient R. M. was used as an illustration as representative of this group of patients. Of the eight active disease patients, only four with measurements over 1 mo were presented (H. D., R. L. and T. W. died during treatment; B. B. changed from active disease to NED). The other four patients had all of their determinations within 1 mo and did not show much variation, so they were not included in Fig. 4 .
ICS levels and survival. At least 8 mo after diagnosis all 29 patients in stages I-IVs survived up to the last follow-up. Of the 32 stage IV patients, 11 were surviving as long as the study was carried out. As a result of the retrospective nature of the data, the ICS measurements were not made at fixed intervals, so they do not lend themselves directly to survival analysis. However, restricting attention only to those 24 stage IV patients who had ICS measurements during treatment with at least 3 mo of therapy, it was found that no correlation existed between the ICS values and the over 10% of these sera are hypocomplementemic. In one report of a detailed study of serum of a patient with untreated chronic lymphocytic leukemia associated with hypocomplementemia and cryoglobulinemia, the immune complexes were identified and isolated, and it was found that they were made up of IgM antilymphocyte antibody and lymphocyte membrane antigens (32) . Using the 1251-Clq deviation test, sera from patients with various malignancies, melanoma, breast, head and neck, gynecological, lung, colon, and rectal cancer were studied, and it was found that many patients had ICS in their serum and the levels were sometimes as high as those detected in patients with systemic lupus erythematosus (33) . By sucrose density gradient ultracentrifugation of some sera studied, the ICS were shown to be 19S or greater. With the Limulus test (34), we demonstrated that DNA and endotoxin, substances known to interfere in the Clq deviation test, were negligible in sera of 50 cancer patients with high levels of ICS. The above studies were carried out with adult cancer sera by the '251-Clq deviation test, and the levels of ICS determined were not correlated with the extent or stages of cancer or treatment.
In this study we investigated sera of patients with neuroblastoma using the Raji cell radioimmunoassay (28) , with particular emphasis on the correlation of levels of ICS with stage of disease and changes attributable to treatment. Patients were classified according to a scheme based on the extent of dissemination ofthe neuroblastoma at the time of diagnosis, ranging from stage I when the tumor is confined to the organ or tissue of origin to stage IV with distant metastasis in bones, distant lymph nodes, marrow, or soft tissues. We investigated 123 serum samples from 67 patients before, during, and after therapy and showed that there was a close correlation between the levels ofcomplexes, stage ofdisease and treatment. The levels increased with the stage of disease and decreased during and after treatment. The increase of levels with respect to different stages was most evident in the before treatment group. Significant differences among the four stages were evident (P < 0.01). In particular, this was a result of the higher values of ICS in stage IN which was significantly higher than all other stages combined (P < 0.005). Patients with more localized disease had less chemotherapy, whereas patients with stage IV were treated more intensively. Despite this very intensive chemotherapy, that is also immunosuppressive, these patients had the highest levels of circulating immune complexes. The differences in chemotherapy in the various stages therefore did not affect significantly the levels of immune complexes. When the levels of ICS were subdivided by the course of treatment, there was a significant difference among the three groups before, during, and after treatment (P < 0.05). Within the no evidence of disease group, the difference of' levels of ICS between during treatment and after treatmiienit was not significant, and the differences across the stages were also not significant. In contrast, within the stage IV group the differences among before, during, and after treatment groups were significant (P < 0.05). Further, when it was possible to obtain serum samples serially, advancing disease and treatment were associated with changes in levels for ICS. For example. in two patients' sera where five or more determiniations were dcone initially and during treatmiienit, ICS levels decreased progressively during treatment.
Studies of C and C components did not give such a clear relationship. Although a significanit decrease compared to normal hemolytic levels of Cl (P < 0.025) were found in the active disease group and C3 (P < 0.005) was low in patients without evidence oftumor, the remaining C components were found to fall in the normal range or not to be significantly different fromii those of the normal controls. This could be due to the large variability in each test and to the small number of samples available for analysis. The influence of acutephase reactivity on certain C components (35) tendIs to elevate levels of these components thus masking the changes of pathological C component use. This phenomenon may provide a likely explanation of our findings of normal or even elevated values for most comii-ponents despite the presence of ICS in the circulation. Of interest, are our observations of some high C3 levels determined immunochemically that were associated with low hemolytic levels of C3 offreshly drawn neuroblastoma sera. Analysis of three such sera by immunoelectrophoresis showed that this discrepancy was attributable to cleavage of C3. Quantitative studies of split products of C3 and factor B might be a more sensitive method to study C activation as shown by Nydegger et al. (36) , and such studies should be carried out in children with neuroblastoma and other forms of cancer. Recently, Gerson et al. (37) have shown that C3 levels determined immunochemically are elevated in neuroblastoma patients when the disease is active. These investigators, however, did not study C3 by hemolytic analysis.
The presence of immune complexes in various malignancies established by different techniques has also been reported by other investigators and in some studies fixation of immune complexes in the glomeruli of patients with leukemia, lymphoma, Hodgkin's disease (38, 39) , colon carcinoma (40), lung carcinoma (41), African Burkitt's lymphoma (42) , melanoma (43, 44) , and other malignancies (43, 44, 45) has been found. Circulating immune-complex-like substances have been reported in patients with melanoma (43, (46) (47) (48) (49) , breast cancer (50), lung cancer, colon cancer (48) (49) (50) , leukemias (51, 52 ), Hodgkin's disease (53) (54) (55) , and nonHodgkin's lymphomas (56) . In a few studies, the relationship of the amount of ICS to stage of disease has been reported (43, 48, 52, 53) . Although Hellstrom et al. (10) used the colony inhibition technique and Jose and Seshardi (15) used a counterelectrophoresis method for detecting complexes in patients with human neuroblastoma, no detailed studies as those discussed here correlating levels of ICS with stage of neuroblastoma and treatment have been reported.
In unpublished preliminary observations, we have also noted that levels of ICS are significantly greater in advanced disease than in the earlier stages, in childhood Hodgkin's disease, adult colon-rectal disease, and breast cancer.
Most important, of course, is to determine the composition of these ICS and further to characterize them by physical, chemical studies. However, based on our survival data, the ICS levels may be of significant value in prognosis of neuroblastoma. Further, the determination of ICS may serve to complement contemporary methods for staging and determining the efficacy of treatment in children with this disease.
